The effect of statins on the no-reflow phenomenon: An observational study in patients with hyperglycemia before primary angioplasty

American Journal of Cardiovascular Drugs

Volumn 9, Issue 2, 2009, Pages 81-89

  Zhao, Jing Lin ^a   Yang, Yue Jin ^a   Pei, Wei Dong ^a   Sun, Yu Hua ^a   Chen, Ji Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DRUG USE; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD GLUCOSE; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PREDICTIVE VALUE OF TESTS;

EID: 63849286356     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200909020-00002     Document Type: Article

References (24)

1. Keeley EC, Grines CL. Primary percutaneous coronary intervention for every patient with ST-segment elevation myocardial infarction: what stands in the way? Ann Intern Med 2004; 141: 298-304
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20
3. Stone GW, Grines CL, Browne KF, et al. Predictors of in-hospital and 6 month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995; 25: 370-7
4. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-9
5. Ito H, Maruyama A, Iwakura K. Clinical implications of the 'no-reflow' phenomenon: a predictor of complications and left ventricular remodeling in perfused anterior wall myocardial infarction. Circulation 1996; 93: 223-8
6. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-72
7. Oswald GA, Corcoran S, Yudkin JS, Prevalence and risk of hyperglycemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1984; 1: 1264-7
8. Iwakura K, Kojima S, Sakamoto T, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41: 1-7
9. Obermaier R, Von Dobschuetz E, Drognitz O, et al. Ischemic preconditioningattenuates capillary no-reflow and leukocyte adherence in postischemic pancreatitis. Langenbecks Arch Surg 2004; 389: 511-6
10. Zhao JL, Yang YJ, Cui CJ, et al. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol 2006; 149: 243-9
11. Kersten JR, Schmeling TJ, Orth KG, et al. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol Heart Circ Physiol 1998; 275: H721-5
12. Kersten JR, Toller WG, Gross ER, et al. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000; 278: H1218-24
13. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-54
14. Bolk J, van der Ploeg T, Cornel JH, et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 2001; 79: 207-14
15. Capes SE, HuntD,Malmberg K, et al. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-8
16. Oswald GA, Yudkin JS. Thyperglycaemia following acute myocardial infarction: the contribution of undiagnosed diabetes. Diabet Med 1987; 4: 68-70
17. Hokama JY, Ritter LS, Davis-Gorman G, et al. Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia. J Diabetes Complicat 2000; 14: 96-107
18. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903
19. Kersten JR, Montgomery MW, Ghassemi T, et al. Diabetes and hyperglycemia impair activation of mitochondrial KATP channels. Am J Physiol Heart Circ Physiol 2001; 280: H1744-50
20. Lefer DJ, Scalia R, Jones SP, et al. HMG-CoAreductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 2001; 15: 1454-6
21. Bayorh MA, Ganafa AA, Eatman D, et al. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens 2005; 18: 1496-502
22. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-57
23. Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38: 472-7
24. Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42: 1739-46